Mô hình điều trị thực tiễn và kết quả sống sót cho bệnh ung thư phổi không tế bào nhỏ giai đoạn tiến triển trong thời kỳ trước liệu pháp miễn dịch tại Bồ Đào Nha: một phân tích hồi cứu từ sáng kiến I-O Optimise

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. GLOBOCAN. Global Cancer Observatory. [Internet]. 2018. Available from: https://gco.iarc.fr/. Accessed 13 Aug 2019. Lopes JM, Goncalves FR, Borges M, Redondo P, Laranja-Pontes J. The cost of cancer treatment in Portugal. Ecancermedicalscience. 2017;11:765. Borges M, Gouveia M, Alarcao J, Sousa R, Teixeira E, Barata F, et al. Cost and burden of non-small cell lung cancer's in Portugal. Value Health. 2014;17(7):A626. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv192–237. Raju S, Joseph R, Sehgal S. Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther. 2018;7:63–75. Qin H, Wang F, Liu H, Zeng Z, Wang S, Pan X, et al. New advances in immunotherapy for non-small cell lung cancer. Am J Transl Res. 2018;10(8):2234–45. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. Garassino MC, Cho BC, Kim JH, Mazieres J, Vansteenkiste J, Lena H, et al. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19(4):521–36. Ekman S, Griesinger F, Baas P, Chao D, Chouaid C, O'Donnell JC, et al. I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. Future Oncol. 2019;15(14):1551–63. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136(1):260–71. Castro AS, Parente B, Goncalves I, Antunes A, Barroso A, Conde S, et al. Epidermal growth factor receptor mutation study for 5 years, in a population of patients with non-small cell lung cancer. Rev Port Pneumol. 2013;19(1):7–12. Aguiar F, Fernandes G, Queiroga H, Machado JC, Cirnes L, Souto Moura C, et al. Overall survival analysis and characterization of an EGFR mutated non-small cell lung cancer (NSCLC) population. Arch Bronconeumol. 2018;54(1):10–7. de Castro J, Tagliaferri P, de Lima VCC, Ng S, Thomas M, Arunachalam A, et al. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study. Eur J Cancer Care. 2017;26(6):e12734. Ramlau R, Cufer T, Berzinec P, Dziadziuszko R, Olszewski W, Popper H, et al. Epidermal growth factor receptor mutation-positive non-small-cell lung cancer in the real-world setting in Central Europe: the INSIGHT study. J Thorac Oncol. 2015;10(9):1370–4. Verleye L, De Gendt C, Vrijens F, Schillemans V, Camberlin C, Silversmit G, et al. Patterns of care for non-small cell lung cancer patients in Belgium: a population-based study. Eur J Cancer Care. 2018;27(1):e12747. Ekman S, Sørensen JB, Brustugun OT, Horvat D, Patel D, Rosenlund M, et al. Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: a SCAN-LEAF study analysis from the I-O Optimise initiative. Ann Oncol. 2019;30(Supplement_2):ii17. Abstract 47P. https://doi.org/10.1093/annonc/mdz070.005. Sørensen JB, Ekman S, Brustugun OT, Horvat D, Patel D, Rosenlund M, et al. Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: a SCAN-LEAF study analysis from the I-O Optimise initiative. Ann Oncol. 2019;30(Supplement_2):ii16–ii17. Abstract 46P. https://doi.org/10.1093/annonc/mdz070.004. Caballero Vazquez A, Garcia Flores P, Romero Ortiz A, Del Moral RG, Alcazar-Navarrete B. Changes in non-small cell lung cancer diagnosis, molecular testing and prognosis 2011-2016. J Thorac Dis. 2018;10(9):5468–75. von Verschuer U, Schnell R, Tessen HW, Eggert J, Binninger A, Spring L, et al. Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study. Lung Cancer. 2017;112:216–24. Ess SM, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, et al. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: a comprehensive evaluation of real world practices. Eur J Cancer Care. 2017;26(6):e12721. Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C. Epidemiological characteristics, EGFR status and management patterns of advanced non-small cell lung cancer patients: the Greek REASON observational registry study. Anticancer Res. 2018;38(6):3735–44. Schuette W, Schirmacher P, Eberhardt WE, Fischer JR, von der Schulenburg JM, Mezger J, et al. EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study. Cancer Epidem Biomar. 2015;24(8):1254–61. Ramlau R, Krawczyk P, Dziadziuszko R, Chmielewska I, Milanowski J, Olszewski W, et al. Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: experience of the INSIGHT study in Poland. Oncol Lett. 2017;14(5):5611–8. Schuette W, Schirmacher P, Eberhardt WEE, Dietel M, Zirrgiebel U, Muehlenhoff L, et al. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study. BMC Cancer. 2018;18(1):135. Aarts MJ, van den Borne BE, Biesma B, Kloover JS, Aerts JG, Lemmens VE. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy. Int J Cancer. 2015;136(5):E387–95. Peters BJM, Cramer-Vd Welle CM, Smit AAJ, Schramel F, van de Garde EMW. Trends in prescribing systemic treatment and overall survival for non-small cell lung cancer stage IIIB/IV in the Netherlands: 2008-2012. Cancer Epidemiol. 2017;51:1–6. Sørensen JB, Ekman S, Brustugun OT, Horvat P, Patel D, Rosenlund M, et al. Evolution of overall survival in patients with incident NSCLC in Denmark and Sweden: a SCAN-LEAF study analysis from the I-O Optimise initiative. Presented at: 9th European Lung Cancer Congress; 10–13 April 2019; Geneva, Switzerland. 2019. Poster number: 46P. Snee M, Cheeseman S, Thompson M, Lacoin L, Sopwith W, Chaib C, et al. P2.01–91 Treatment patterns in patients with stage IIIB-IV NSCLC in clinical practice: retrospective analysis of a UK trust database. J Thorac Oncol. 2018;13(10, Supplement):S700. Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morere JF, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol. 2005;16(4):602–10. Raez LE, Santos ES, Lopes G, Rosado MF, Negret LM, Rocha-Lima C, et al. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer. 2006;53(3):347–53. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–22. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–40. Moro-Sibilot D, Smit E, de Castro CJ, Lesniewski-Kmak K, Aerts J, Villatoro R, et al. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer. 2015;88(2):215–22.